ORCA Opti

Industries · India

Pharmaceuticals

Protect data integrity across India's pharma industry. ORCA Opti brings your risks, controls and AI governance into one living system of record, inside your Safe Zone.

Regulation

Aligned to Indian regulation

ORCA Opti maps to the obligations Indian organisations face, and keeps your evidence ready.

Digital Personal Data Protection Act 2023

Digital Personal Data Protection Act 2023

Consent, data principal rights and breach obligations under the DPDP Act.

CERT-In directions

CERT-In directions

Mandatory cyber incident reporting within tight timeframes, with the logs to back it up.

RBI & SEBI cyber frameworks

RBI & SEBI cyber frameworks

Sector cyber security and resilience expectations for financial services.

ISO 27001 & IT Act 2000

ISO 27001 & IT Act 2000

Information security management and reasonable security practices, mapped.

AI governance

AI governance

Safe, accountable AI aligned with emerging MeitY guidance.

Data localisation

Data localisation

Keep regulated data where it needs to stay, inside your Safe Zone.

For Pharmaceuticals

See ORCA Opti for Indian Pharma

Indian pharma is the world's third-largest by volume and the largest supplier of generics to the US. With USFDA, EU EMA, the revised Schedule M and CDSCO all watching, plus IP-rich R&D pipelines and global CMO and CDMO contracts, every batch record and every system has to be evidence-grade. ORCA Opti brings data integrity, quality and security into one programme.

Data integrity, ALCOA+ ready

Data integrity, ALCOA+ ready

21 CFR Part 11, EU Annex 11 and revised Schedule M data integrity controls mapped, so USFDA and EMA inspections land cleanly.

R&D, batch records and IP in the Safe Zone

R&D, batch records and IP in the Safe Zone

Molecule research, formulation records and CMO documents stay inside the Safe Zone, with AI Guardian blocking accidental disclosure to external AI.

USFDA, EMA and global customer audits

USFDA, EMA and global customer audits

Inspection-ready evidence for Form 483 responses, EMA inspections and global customer quality audits, kept current between visits.

Schedule M and WHO-GMP without spreadsheets

Schedule M and WHO-GMP without spreadsheets

Revised Schedule M, WHO-GMP and CDSCO records assembled in a living quality system, ready for inspection at short notice.

The pressure

What pharma QA and IT directors are facing

Inspector expectations have moved beyond paper. Every system in the value chain now has to demonstrate integrity, security and provenance under pressure.

USFDA Form 483 and Warning Letters

USFDA Form 483 and Warning Letters

Data integrity findings drive most Warning Letters. Without evidence-grade controls, a single observation can lose a market for years.

Global customer quality audits

Global customer quality audits

Innovator pharma customers, US distributors and EU marketing authorisation holders audit your quality system every year. Evidence must be ready, current and trusted.

IP and formulation leakage

IP and formulation leakage

Molecule formulations, process IP and clinical data leaking to external AI tools is the new top exfiltration risk. AI Guardian shuts it down at the prompt.

Ransomware on manufacturing

Ransomware on manufacturing

Manufacturing is the most-attacked sector globally. Ransomware on MES, LIMS or batch-execution systems can halt production and create market-supply risk.

Frameworks built in

Inspection-ready, every cycle

ORCA Opti ships with the standards Indian pharma actually runs on, from CDSCO to ICH. Controls pre-mapped, evidence structured and reporting current.

Revised Schedule M & CDSCO

Revised Schedule M (2024), CDSCO licensing and Indian GMP records mapped to a living quality system.

21 CFR Part 11 & EU Annex 11

Electronic records, electronic signatures and computerised system validation evidence aligned to USFDA and EMA expectations.

WHO-GMP & PIC/S

World Health Organization GMP and Pharmaceutical Inspection Co-operation Scheme records assembled for global market access.

ISO 9001 & ISO 13485

Quality management for pharmaceuticals and combination devices, mapped to controls and management review cycles.

CERT-In & DPDP Act

6-hour incident reporting and personal data protection obligations integrated with quality and audit workflows.

ICH Q7-Q10, Q12 & Pharma 4.0

International Council for Harmonisation guidelines, product lifecycle management and digital pharma maturity models, supported as you scale.

See ORCA Opti for Pharmaceuticals in India.

Work through a guided check with Opti Assist and get an immediate view of where you stand.

Join our mailing list

News and updates from ORCA Opti.